Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elsa Ferris
Institution:
Institute of Cancer Research
Observed institution:
Institute of Cancer Research
ORCID:
0009-0008-4657-0697
Observed ORCID:
0009-0008-4657-0697
OpenAlex ID:
A5138731841
Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial
2026
·
Andrew Hall
, James Croft
, et al.
·
British Journal of Haematology
·
1
Clinical, cytogenetic, and germline genetic determinants of arterial thromboembolism in IMiD-treated multiple myeloma
2026
·
Sina A. Beer
, David A. Cairns
, et al.
·
Blood Cancer Journal
PDF
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial
2026
·
Martin F Kaiser
, Rachel H Phillip
, et al.
·
The Lancet Oncology
OA-62 Re-Defining Ultra-High-Risk Myeloma by Combining Genomic and Transcriptional Risk Assessment: An Exploratory Study of the UKMRA OPTIMUM/MUKnine Trial
2026
·
Sina A. Beer
, Andrew Hall
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
4
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type